GERON CORP Additional Paid in Capital, Common Stock
GERON CORP (GERN) had Additional Paid in Capital, Common Stock of $2.09 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $2.09B.
- 2026-03-31: Additional Paid in Capital, Common Stock $2.09B.
- 2025-12-31: Additional Paid in Capital, Common Stock $2.08B.
- 2025-09-30: Additional Paid in Capital, Common Stock $2.07B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $2.09B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $2.09B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.08B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $2.07B 10-Q · filed 2025-11-07 |
| 2025-06-30 | $2.07B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.06B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.05B 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.04B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.03B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.00B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.84B 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.84B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.80B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.78B 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.49B 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.48B 10-Q · filed 2022-11-07 |
| 2022-06-30 | $1.47B 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.40B 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.40B 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.39B 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.39B 10-Q · filed 2021-08-16 |
| 2021-03-31 | $1.38B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.37B 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.36B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.36B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.22B 10-Q · filed 2020-05-28 |
| 2019-12-31 | $1.21B 10-K · filed 2021-03-11 |
| 2019-09-30 | $1.20B 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.19B 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.19B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.19B 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.19B 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.18B 10-Q · filed 2018-07-31 |
| 2018-03-31 | $1.09B 10-Q · filed 2018-05-10 |
| 2017-12-31 | $1.09B 10-K · filed 2019-03-07 |
| 2017-09-30 | $1.09B 10-Q · filed 2017-11-01 |
| 2017-06-30 | $1.08B 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.08B 10-Q · filed 2017-05-09 |
| 2016-12-31 | $1.08B 10-K · filed 2018-03-16 |
| 2016-09-30 | $1.08B 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.08B 10-Q · filed 2016-08-03 |
| 2016-03-31 | $1.07B 10-Q · filed 2016-05-05 |
| 2015-12-31 | $1.07B 10-K · filed 2017-03-01 |
| 2015-09-30 | $1.07B 10-Q · filed 2015-11-05 |
| 2015-06-30 | $1.07B 10-Q · filed 2015-08-05 |
| 2015-03-31 | $1.06B 10-Q · filed 2015-05-07 |
| 2014-12-31 | $1.06B 10-K · filed 2016-03-10 |
| 2014-09-30 | $1.06B 10-Q · filed 2014-11-05 |
| 2014-06-30 | $1.05B 10-Q · filed 2014-08-11 |
| 2014-03-31 | $1.05B 10-Q · filed 2014-05-01 |
| 2013-12-31 | $952.40M 10-K · filed 2015-03-11 |
| 2013-09-30 | $945.24M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $943.52M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $942.19M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $939.87M 10-K · filed 2014-03-17 |
| 2012-09-30 | $938.08M 10-Q · filed 2012-11-02 |
| 2012-06-30 | $936.72M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $935.07M 10-Q · filed 2012-05-07 |
| 2011-12-31 | $932.07M 10-K · filed 2013-03-15 |
| 2011-09-30 | $928.90M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $925.10M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $881.36M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |